CareDx Inc ((CDNA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The AlloSure Lung Assessment and Metagenomics Outcomes Study (ALAMO) is a prospective, multi-center registry led by CareDx, aimed at evaluating the diagnostic performance of AlloSure Lung in detecting rejection and infections in lung transplant recipients. This study is significant as it seeks to enhance post-transplant care through improved surveillance methods.
The intervention being tested is LungCare™, which includes AlloSure®-Lung, AlloMap Lung, and HistoMap. These are designed to monitor lung transplant patients for signs of rejection and infection, thereby improving patient management and outcomes.
The study is observational, using a case-control model with a prospective time perspective. It involves a registry of patients and collects data over a three-year period to assess the real-world application of LungCare.
The study began on October 29, 2021, with an estimated completion date yet to be confirmed. The latest update was submitted on July 30, 2025, indicating ongoing recruitment and data collection efforts.
For investors, this update could positively influence CareDx’s stock performance by showcasing the company’s commitment to advancing transplant care. The study’s outcomes may also set a benchmark in the industry, potentially affecting competitors who are also focusing on post-transplant monitoring solutions.
The study is ongoing, with further details available on the ClinicalTrials portal.